| Whitney Bonner Sparks, NP | |
|
26 3rd St, Belmont, MS 38827-7737 | |
| (662) 454-4520 | |
| (662) 454-4521 |
| Full Name | Whitney Bonner Sparks |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 26 3rd St, Belmont, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265865992 | NPI | - | NPPES |
| 08781307 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R883463 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Mississippi Medical Ctr Hha | Tupelo, MS | Home health agency |
| Kindred At Home | Tupelo, MS | Home health agency |
| Tishomingo Health Services Inc | Iuka, MS | Hospital |
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tishomingo Health Services, Inc. | 2466354303 | 14 |
News Archive
The prospect of a paycheck, good grade, or promotion wonderfully concentrates the mind, and researchers have now identified the brain circuitry responsible for such reward-motivated learning.
A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function – a painstaking process often requiring years of laboratory trial and error.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."
› Verified 8 days ago
| Entity Name | Tishomingo Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548376700 PECOS PAC ID: 2466354303 Enrollment ID: O20040122000374 |
News Archive
The prospect of a paycheck, good grade, or promotion wonderfully concentrates the mind, and researchers have now identified the brain circuitry responsible for such reward-motivated learning.
A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function – a painstaking process often requiring years of laboratory trial and error.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."
› Verified 8 days ago
| Entity Name | North Mississippi Medical Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053469486 PECOS PAC ID: 6103736665 Enrollment ID: O20040127000582 |
News Archive
The prospect of a paycheck, good grade, or promotion wonderfully concentrates the mind, and researchers have now identified the brain circuitry responsible for such reward-motivated learning.
A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function – a painstaking process often requiring years of laboratory trial and error.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Whitney Bonner Sparks, NP 450 E President Ave, Tupelo, MS 38801-5599 Ph: (662) 377-4685 | Whitney Bonner Sparks, NP 26 3rd St, Belmont, MS 38827-7737 Ph: (662) 454-4520 |
News Archive
The prospect of a paycheck, good grade, or promotion wonderfully concentrates the mind, and researchers have now identified the brain circuitry responsible for such reward-motivated learning.
A single strand of plant or animal DNA may contain tens of thousands of genes, each programmed to produce a specific protein essential for the growth or survival of the organism. The challenge for geneticists is to isolate individual genes and determine their function – a painstaking process often requiring years of laboratory trial and error.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."
› Verified 8 days ago
Heather Larue Edmondson, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 3rd St, Belmont, MS 38827 Phone: 662-454-3401 | |
Lacy Diane Estes, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 26 3rd St, Belmont, MS 38827 Phone: 662-454-4520 Fax: 662-454-4521 | |
Dr. Toni Armstrong, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 | |
Angela James, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 26 3rd St, Belmont, MS 38827 Phone: 662-454-7170 | |
Lisa Collums Rhea, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 Fax: 662-454-1062 | |
Misty Leigh Glidewell, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 Fax: 662-454-1062 |